Stock & Company Details
Editas Medicine Inc $EDIT
Price:
46,691,331
98M
$497M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
-2.80
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Health Technology
EDIT technical indicators
Latest Editas Medicine Inc (EDIT) technical indicators as of 2026-07-01: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
63.71 1.4%
MACD:
0.07 78.0%
SMA 50:
$2.90 0.2%
SMA 200:
$2.68 0.1%
EMA 20:
$2.87 1.5%
Bollinger Bands:
3.26 / 2.23
Stochastic:
91.29 0.3%
ADX 14:
17.56 9.9%
ATR 14:
0.26 3.1%
CCI 20:
193.13 6.6%
OBV:
-691.96K 81.2%
ROC 12:
31.20% 4.8%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Finance Bot
Ask your questions
Start by typing a question below.
